Celularity Inc. Class A Common Stock (CELU) Stock Price

CELUStock

$0.80−79.56%52W

Market Cap$23.18M

P/E—

PEG Ratio—

Div yield—

Beta0.57

CELU Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-58.89%

Price vs S&P 500 (4W)-1.12%

VGM Score41.88

Book Value / Share (Quarterly)$0.39

P/TBV (Annual)1.57x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.88%

Cash Flow / Share (Quarterly)$-0.46

Price vs S&P 500 (YTD)-42.16%

Gross Margin (TTM)24.39%

Net Profit Margin (TTM)-345.45%

EPS (TTM)$-3.59

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-3.59

EPS (Annual)$-3.58

ROI (Annual)-113.87%

Gross Margin (Annual)24.39%

Net Profit Margin (5Y Avg)-340.92%

Cash / Share (Quarterly)$0.21

Revenue Growth QoQ (YoY)-77.37%

ROA (Last FY)-43.53%

Revenue Growth TTM (YoY)-51.03%

EBITD / Share (TTM)$-2.79

ROE (5Y Avg)-245.63%

Operating Margin (TTM)-274.53%

Cash Flow / Share (Annual)$-0.35

P/B Ratio2.29x

P/B Ratio (Quarterly)5.29x

Net Income / Employee (Annual)$-745,700

EV / Revenue (TTM)2.33x

Net Interest Coverage (TTM)-13.27x

ROA (TTM)-77.94%

EV / EBITDA (TTM)4.44x

EPS Incl Extra (Annual)$-3.58

Current Ratio (Annual)0.39x

Quick Ratio (Quarterly)0.14x

3-Month Avg Trading Volume0.12M

52-Week Price Return-79.56%

EV / Free Cash Flow (Annual)3.50x

Revenue / Employee (TTM)$215,900

Tangible BV / Share (Quarterly)$0.34

P/S Ratio (Annual)0.76x

Asset Turnover (Annual)0.41x

52-Week High$4.01

Operating Margin (5Y Avg)-370.10%

EPS Excl Extra (Annual)$-3.58

26-Week Price Return-47.65%

Quick Ratio (Annual)0.28x

13-Week Price Return-13.78%

Total Debt / Equity (Annual)4.75x

Current Ratio (Quarterly)0.15x

Enterprise Value$61.90M

Asset Turnover (TTM)0.23x

Book Value / Share Growth (5Y)-57.40%

Revenue / Employee (Annual)$215,900

Inventory Turnover (Annual)2.69x

Pretax Margin (Annual)-345.44%

Cash / Share (Annual)$0.03

3-Month Return Std Dev100.98%

Gross Margin (5Y Avg)34.35%

Net Income / Employee (TTM)$-745,700

ROE (Last FY)-654.89%

Net Interest Coverage (Annual)-13.27x

EPS Basic Excl Extra (Annual)$-3.58

Receivables Turnover (TTM)2.92x

Total Debt / Equity (Quarterly)4.79x

EPS Incl Extra (TTM)$-3.59

Receivables Turnover (Annual)2.57x

ROI (TTM)-92.04%

P/S Ratio (TTM)0.76x

Pretax Margin (5Y Avg)-340.87%

Revenue / Share (Annual)$1.04

Tangible BV / Share (Annual)$1.58

Price vs S&P 500 (52W)-97.87%

Year-to-Date Return-30.20%

5-Day Price Return5.17%

EPS Normalized (Annual)$-3.58

ROA (5Y Avg)-40.28%

Net Profit Margin (Annual)-345.45%

Month-to-Date Return21.96%

Cash Flow / Share (TTM)$-0.44

EBITD / Share (Annual)$-2.79

Operating Margin (Annual)-274.53%

ROI (5Y Avg)-86.18%

LT Debt / Equity (Quarterly)4.07x

EPS Basic Excl Extra (TTM)$-3.59

P/TBV (Quarterly)8.85x

P/B Ratio (Annual)5.20x

Inventory Turnover (TTM)6.71x

Pretax Margin (TTM)-345.44%

Book Value / Share (Annual)$0.39

Price vs S&P 500 (13W)-16.57%

Beta0.57x

Revenue / Share (TTM)$0.93

ROE (TTM)-272.44%

52-Week Low$0.56

vGradeB

gGradeF

mGradeD

vgmGradeC

CELU Earnings Surprise History

Q1 23-4.10est. -2.40

Q2 23-2.70est. -0.30

CELU Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
CELUCelularity Inc. Class A Common Stock	B	F	D	$0.80
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Celularity Inc. Class A Common Stock

Celularity is a clinical-stage biotechnology company developing placental-derived cell therapies for cancer, immunological, infectious, and degenerative diseases. Its pipeline includes natural killer cells, engineered T cells (including CAR-T), and mesenchymal stromal cells. The company operates three business segments—Cell Therapy, Degenerative Disease, and Bio-banking—with the bio-banking division currently serving as the primary revenue source.